-
Part 3 | Session 4 Session 3.4: Debates
-
Part 1 | Session 1 Session 1.1: Next Level Structural Heart Interventions
-
Part 1 | Session 2 Session 1.2: Live Cases and Discussion
-
Part 1 | Session 4 Session 1.3: Practical Perspectives in the Context of TAVI
-
Part 1 | Session 5 Session 1.4: Live Cases and Discussions
-
Part 1 | Session 6 BREAKOUT: Current Data and Future Direction in LAAC
-
Part 2 | Session 1 Session 2.1: Strategies for Calcified Coronary Lesions Anno 2022
-
Part 2 | Session 2 Session 2.2: Live Cases and Discussion
-
Part 2 | Session 4 Session 2.3: Practical Pearls Towards a More Advanced CTO Programme
-
Part 2 | Session 5 Session 2.4: Live Cases and Discussion
-
Part 2 | Session 7 BREAKOUT: Coronary Physiology in STEMI patients today: Why? When? How?
-
Part 3 | Session 1 Session 3.1 & 3.2: Keynote & Controversies
Following on from the success of 2021's inaugural edition, Transcatheter Interventions Online 2022 brings together a world-class faculty to provide expert insight and educational learning on the latest developments in interventional management.
Combining expert opinion and discussion, presentations, and live cases from centres on both sides of the Atlantic, TIO 2022 delivers best-in-class learning, supporting the latest in diagnosis, treatment strategies and patient management.
Note, the live version of this session was CME accredited; this on-demand version is not.

Key Learning Objectives
- Describe the practical implications of TAVI in the context of coronary artery disease, atrioventricular valve disease and transcatheter heart valve degeneration
- Select appropriate tools for calcified coronary artery disease, including mechanical circulatory support and invasive imaging techniques
- Understand coronary physiology, novel recanalization and goal-oriented planning for chronic total occlusion
- Evaluate the role of novel oral anticoagulants in transcatheter aortic valve implantation
- Discuss the need for gender-specific trials and renal denervation
Target Audience
- Interventional Cardiologists
- Surgeons with an interest in transcatheter treatment strategies for coronary and structural heart disease
- Interventional Cardiology Nurses
More from this programme
Part 1
Day One: Structural Heart Disease
Part 2
Day Two: Coronary Heart Disease: High Risk & Complex PCI
Faculty Biographies

Roxana Mehran
Professor of Medicine, Cardiology and Professor of Population Health Science and Policy
Roxana Mehran is Professor of Medicine, Cardiology and Professor of Population Health Science and Policy at the Icahn School of Medicine at Mount Sinai in New York. She is also Director of Interventional Cardiovascular Research and Clinical Trials at The Zena and Michael A Weiner Cardiovascular Institute at Mount Sinai Hospital where, over the past 5 years, she has led the development of a globally respected data and clinical coordination centre to support large, multicentre, multinational clinical trials designed to help improve outcomes and quality of life for patients undergoing interventional cardiovascular procedures. In recent years, her work has had a special emphasis on gaining a deeper understanding of anticoagulation and antiplatelet regimens post angioplasty and transcatheter valve replacement; and collection and interpretation of sex-specific data in cardiovascular clinical trials.
Roxana serves on editorial board of multiple peer reviewed journals, including …

Nicolas M Van Mieghem
Medical Director
Prof Nicolas Maria Van Mieghem is an Interventional cardiologist at Thoraxcenter, Erasmus MC, Rotterdam, NL decided to pursue a career that would help others. “I enjoy the feeling of being able to help someone or do something important for them". His father was a general cardiologist and one of his biggest influences early in his career.
Prof Van Mieghem initially intended to train as a cardiac surgeon but decided to specialise in interventional cardiology instead, following advice from a mentor. This decision was cemented when he read the first-in-human case report of transcatheter aortic valve implantation (TAVI) in Circulation by Alain Cribier in 2002. Prof Van Mieghem believes that great cardiologist genuinely cares for their patients. He names Gary Roubin, Dr Manu Malbrain and Professor Patrick Serruys among his mentors.
His current research focuses on cerebral embolic protection during TAVI and the search for improved…

Kendra J Grubb
Surgical Director
Dr Kendra Grubb is the surgical director of the Emory Structural Heart and Valve Center. She is also an associate professor of surgery at Emory University School of Medicine.
Kendra is a champion for women's heart disease and is dedicated to improving the lives of all patients through innovation, collaboration and a patient-centred approach to the treatment of cardiovascular disease.
Her clinical interests include valve repair or replacement, coronary artery bypass graft surgery (CABG), transcatheter aortic valve replacement (TAVR) and hybrid coronary revascularization.
Dr Grubb research interests are innovative cardiac surgery technologies. She has led and participated in multiple clinical trials of innovative cardiac surgery technologies, including studies of transcatheter aortic valve replacement (TAVR), MitraClip percutaneous therapy and the GORE® conformable TAG® thoracic endoprosthesis for the primary treatment of…

David Hildick-Smith
Prof David Hildick-Smith is Professor of Interventional Cardiology and Consultant Cardiologist at the Sussex Cardiac Centre - the Regional Specialist Unit. He is Director of the Cardiac Research, ex-Treasurer of the British Cardiovascular Interventions Society, and, with more than 20 years experience of Interventional Cardiology, is considered one of the country's leading experts in management of Cardiovascular complaints.
A pioneer of Interventional Cardiology, David is recognised internationally as a leader in cardiovascular diagnosis and treatment.

Lars Søndergaard
Professor Lars Søndergaard is a consultant cardiologist at Rigshospitalet – Copenhagen, Denmark. Professor of Cardiology at University of Copenhagen, he published over 300 peer reviewed articles, and more than 15 textbook chapters. His research interests are focused on adults with congenital heart diseases and catheter-based heart valve interventions, as well as congenital and structural heart diseases. He led the first-in-human transcatheter mitral valve implantation (CardiAQ) in 2012 and he actively participated to several trials, including NOTION (transcatheter vs. surgical aortic valve replacement in patients with aortic stenosis and low surgical risk), and the REDUCE randomised trial (PFO vs anti-platelet therapy after cryptogenic stroke).

Philipp Lurz
University Medical Center Mainz, Mainz, DE
Prof Philipp Lurz is Director of the Department of Cardiology Universitätsmedizin Mainz, Germany. Prior to this, he served as Deputy Head of the Department at Heart Center Leipzig, Germany. Previously, Prof Lurz was a Clinical Research Fellow at Great Ormond Street Hospital for Children NHS Foundation Trust. He completed his education at the University of Leipzig, and is a member of the German Society of Cardiology. Philipp is widely published in leading international peer-reviewed journals.

Joost Daemen
Interventional Cardiologist
Dr Joost Daemen, MD, PhD is a senior interventional cardiologist at the Thorax Center, Erasmus MC, Rotterdam, NL. Dr Daemen obtained his degree in medicine at the Erasmus University Medical Center, Rotterdam in 2005 and did 2 years of internal medicine training and 4 years of general cardiology training at the Thoraxcenter, Rotterdam.
Dr Daemen is actively involved in several drug-eluting stent trials and is Principal Investigator of four trials focusing on the safety and efficacy of renal sympathetic denervation in hypertension, heart failure, vasospastic angina and heart failure. Dr Daemen is a member of the editorial board of EuroIntervention and the Netherlands Heart Journal, member of Young ICIN, and has completed courses in biomedical statistics and device training.

Christian Besler
Christian Besler practices in Leipzig, Germany. Besler is highly rated in 7 conditions, according to data. His top areas of expertise are Tricuspid Regurgitation, Heart Failure with Preserved Ejection Fraction HFpEF, Heart Failure, Heart Valve Repair, and Cardiac Ablation.
His clinical research consists of co-authoring 95 peer-reviewed articles and participating in 4 clinical trials in the past 15 years.